GlassScriptPhysician profile
Scott Russell Freeman
NPI 1851447460
$2,748.88
in general payments reported to CMS, 2019-2025
15 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.24 · 2020: $202 · 2021: $146 · 2022: $188 · 2023: $984 · 2024: $771 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,795.21 | 2022-2025 | Puraply, Novachor, Affinity |
| Abbvie INC. | $373.32 | 2019-2024 | |
| Janssen Biotech, INC. | $122.38 | 2020-2024 | Stelara, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $92.74 | 2023 | Dupixent |
| Genzyme Corporation | $66.77 | 2020 | |
| Ucb, INC. | $57.50 | 2020-2024 | Bimzelx |
| Amgen INC. | $57.05 | 2020-2022 | |
| Hill Dermaceuticals, INC. | $39.36 | 2023 | Tolak |
| Sun Pharmaceutical Industries INC. | $32.91 | 2021-2023 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $27.26 | 2020-2022 | |
| Celgene Corporation | $21.88 | 2019 | |
| Incyte Corporation | $17.28 | 2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.02 | 2025 | Siliq |
| Genentech USA, INC. | $15.75 | 2020 | |
| Dentsply Sirona INC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.